Chiome Bioscience

Chiome Bioscience CROIC

The Cash Return on Invested Capital (CROIC) of Chiome Bioscience (4583.T) as of Oct 18, 2026 is -70.54 %. In the previous year, Cash Return on Invested Capital (CROIC) was -45.45 % — a change of 55.20% (lower).

CROIC

-70.54 %

YoY

55.20%

Last updated:

Cash Return on Invested Capital (CROIC) of Chiome Bioscience is 2025 -70.54 % . Cash Return on Invested Capital (CROIC) of Chiome Bioscience was 2024 -45.45 % . It decreases by 55.20% lower compared to the previous year.

The Chiome Bioscience CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-63.09 JPY
Jan 1, 2019
-58.66 JPY
Jan 1, 2020
-82.68 JPY
Jan 1, 2021
-108.98 JPY
Jan 1, 2022
-60.31 JPY
Jan 1, 2023
-147.60 JPY
Jan 1, 2024
-45.45 JPY
Jan 1, 2025
-70.54 JPY
The Chiome Bioscience CROIC history
YEARCROICYoY
-70.54 %+55.20%
-45.45 %-69.21%
-147.60 %+144.74%
-60.31 %-44.66%
-108.98 %+31.81%
-82.68 %+40.96%
-58.66 %-7.03%
-63.09 %+205.38%
-20.66 %-2.66%
-21.22 %-29.75%
-30.21 %+96.97%
-15.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Chiome Bioscience Stock analysis

What does Chiome Bioscience do? Chiome Bioscience Inc is a Health Care company based in Shibuya-Ku, Japan. The company has 49 employees and went public on December 20, 2011. It operates in the Life Sciences Tools & Services industry. Chiome Bioscience develops and sells antibody drugs using the Autonomous Diversifying Library (ADLib) system. Its business segments include Drug Discovery, focusing on R&D of specific antibodies for pharmaceutical companies, and Drug Discovery Support, which develops lead antibodies for therapeutic drugs through collaborations with pharmaceutical firms in Japan and overseas. Chiome Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chiome Bioscience stock

Cash Return on Invested Capital (CROIC) of Chiome Bioscience is -70.54 % in 2025.

Cash Return on Invested Capital (CROIC) of Chiome Bioscience changed from -45.45 % to -70.54 %, representing a 55.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Chiome Bioscience since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Chiome Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Chiome Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Chiome Bioscience